■对于患有1型糖尿病的儿童和青少年,推荐强化胰岛素方案以达到血糖目标。速效门冬胰岛素(更快门冬胰岛素)是门冬胰岛素(IAsp)的新配方,其中添加了L-精氨酸和烟酰胺以确保配方稳定性。早期吸收,和超快速的行动。这项荟萃分析比较了Aspart和IAsp对1型糖尿病儿童血糖控制的更快效果。这项研究建议用胰岛素治疗糖尿病,尤其是1型糖尿病儿童。
■PubMed,MEDLINE,Embase,科克伦图书馆,WebofScience,从2000年到2023年,谷歌学者在没有语言限制的情况下进行了搜索。血糖监测,HbA1c,护理模式,门冬胰岛素,IAsp,更快,1型糖尿病,和儿科是网格关键字。CochraneQ统计和指数检验了异质性。为了解释异质性,Q=145.99(P值<0.001),=97.26%,随机效应模型用于汇总主要研究结果。随机对照试验的荟萃分析按照PRISMA标准进行。
■发现总体估计测量,即平均差异为5.44[0.45,10.44]和7.71[7.16,8.26],这表明与T1D中的IAsp相比,速效门冬胰岛素组中的HbA1C水平显著降低。然而,与BMI相关的平均差为-0.06[-0.60,0.48],表明无显著降低.
■在抗胰岛素抗体水平高于成人的儿童和青少年中,与IAsp相比,更快的Aspart起病更快,早期暴露更多。因此,在T1D中,速效门冬胰岛素可能比IAsp提供更好的葡萄糖控制。
UNASSIGNED: Intensive insulin regimens are recommended to achieve glycemic goals in children and adolescents with type 1 diabetes. Fast-acting insulin aspart (faster aspart) is a new formulation of insulin aspart (IAsp) in which L-arginine and niacinamide are added to assure formulation stability, early absorption, and ultra-fast action. This meta-analysis compares faster aspart with IAsp for blood sugar control in children with type 1 diabetes. This study suggested treating diabetes with insulin, especially in children with type 1 diabetes.
UNASSIGNED: PubMed, MEDLINE, Embase, Cochrane Library, Web of Science, and Google Scholar were searched from 2000 to 2023 without language restrictions. Blood glucose monitoring, HbA1c, care model, insulin aspart, IAsp, faster aspart, type 1 diabetes, and pediatrics are Mesh keywords. Cochrane Q statistics and index tested heterogeneity. To account for heterogeneity, Q=145.99 (P-value < 0.001) and =97.26%, and the random-effect model was used to aggregate primary study results. The meta-analysis of randomized-controlled trials was conducted in accordance with PRISMA standards.
UNASSIGNED: The overall estimate measure i.e. mean difference was found to be 5.44 [0.45, 10.44] and 7.71 [7.16, 8.26] which indicate significant reduction in the HbA1C level in the fast acting insulin aspart group as compared to the IAsp in T1D. However, the mean difference with respect to BMI was found to be -0.06 [-0.60, 0.48] which indicate non-significant reduction.
UNASSIGNED: Faster aspart had faster onset and more early exposure than IAsp in children and adolescents with greater and more variable anti-insulin antibody levels than adults did. Hence fast-acting insulin aspart may provide better glucose control than IAsp in T1D.